CSIMarket Company Name, Ticker, Competitors, else..
 
Dianthus Therapeutics Inc   (NASDAQ: DNTH)
 
Price: $108.1000 $0.25 0.232%
Day's High: $109.61000061035156 Week Perf: 2.36 %
Day's Low: $ 105.65 30 Day Perf: -1.66 %
Volume (M): 638,468 52 Wk High: $ 117.88
Volume (M$): $ 0 52 Wk Avg: $67.40
Open: $107.06 52 Wk Low: $25.00



 Market Capitalization (Millions $) 6,057
 Shares Outstanding (Millions) 56
 Employees 92
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -192
 Cash Flow (TTM) (Millions $) 38
 Capital Exp. (TTM) (Millions $) 0

Business Description


Dianthus Therapeutics Inc is a biotechnology company focused on developing gene therapy treatments for genetic diseases. They utilize innovative technologies and techniques to deliver therapeutic genes to target cells in the body, aiming to correct the underlying cause of the disease. Their research and development efforts primarily revolve around rare genetic disorders with high unmet medical needs. Dianthus Therapeutics Inc aspires to provide potentially curative treatment options to patients suffering from these conditions.


   Company Address: 7 Times Square, 43rd Floor New York 10036 NY
   Company Phone Number: 999-4055   Stock Exchange / Ticker: NASDAQ DNTH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        2.68% 
MRK        1.33% 
PFE        1.75% 
TEVA   -0.22%    
VRTX        0.82% 
VTRS        3.3% 
• View Complete Report
   



Clinical Study

Dianthus Therapeutics to Showcase Innovations at Upcoming Healthcare Investor Conferences in September

Published Wed, Sep 4 2024 11:00 AM UTC

Dianthus Therapeutics Inc. (NASDAQ: DNTH), a promising player in the biopharmaceutical sector, is gearing up to participate in three significant healthcare investor conferences this September. As the company continues to push the boundaries of research and development in therapeutics, these engagements offer a crucial platform to connect with investors and share insights on ...
Product Service News

DNTH103 A Promising Therapeutic Approach for Multifocal Motor Neuropathy

Published Wed, Jun 12 2024 11:00 AM UTC

Multifocal Motor Neuropathy (MMN) is a debilitating neurological disorder characterized by muscle weakness and atrophy, resulting from damage to the motor nerves. Despite being a rare condition, the impact on patients quality of life is significant. Currently, there are limited treatment options available for MMN, emphasizing the need for effective therapeutics. In this reg...
Shares

Dianthus Therapeutics Grants Inducement Awards to New Employees; Implications for Shareholders Explored

Published Fri, May 3 2024 8:30 PM UTC



In a recent press release, Dianthus Therapeutics, a renowned clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, announced the granting of equity awards to two newly-hired, non-executive employees. Approved by the company s independent Compensation Committee, these inducement gr...
Product Service News

The Potential of DNTH103 in the Treatment of Neurological Disorders: Insights from Dianthus Therapeutics' Oral Presentation at AAN Annual Meeting 2024

Published Thu, Apr 11 2024 11:30 AM UTC

Dianthus Therapeutics, a renowned clinical-stage biotechnology company, recently unveiled promising research findings on their antibody complement therapeutic, DNTH103, at the American Academy of Neurology (AAN) Annual Meeting. This remarkable endeavor aims to revolutionize the treatment landscape for severe autoimmune diseases, particularly those impacting the neurological ...
Shares

Dianthus Therapeutics Accelerates Growth with Inducement Grants to New Employees

Published Fri, Apr 5 2024 8:30 PM UTC

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics, Inc. (Dianthus), a clinical-stage biotechnology company specializing in antibody complement therapeutics for severe autoimmune diseases, has recently made an important announcement. On April 1, 2024, Dianthus granted equity awards to six newly-hired, non-executiv...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4,203.16
Price to Sales (Expected) -
Price to Book 5.17
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.13
Working Capital Ratio 3.45
Leverage Ratio (MRQ) 0.04
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.39 $
Revenues (TTM) 0.03 $
Cash Flow (TTM) 0.67 $
Cash 1.92 $
Book Value 20.92 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 15,663
Net Income per Employee (TTM) -2,089,630
Receivable Turnover Ratio (TTM) 0.9
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -8079.11 %
Net Margin (MRQ) -6598.55 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Dianthus Therapeutics Inc's Segments
License    160.84 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.